GABAergic mediation in the inhibition of hippocampal acetylcholine turnover rate elicited by delta 9-tetrahydrocannabinol.
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D013759:Dronabinol / Q000494:pharmacology*; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D009118:Muscimol / Q000494:pharmacology; D009271:Naltrexone / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D013378:Substantia Nigra / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D009118:Muscimol; D005680:gamma-Aminobutyric Acid; D009271:Naltrexone; D013759:Dronabinol; D000109:Acetylcholine; D004298:Dopamine; D009638:Norepinephrine; D001640:Bicuculline